Wilate, von Willebrand Factor/Coagulation Factor VIII Complex

Generic name: von willebrand factor/coagulation factor viii complex (human)
Dosage form: powder, for intravenous solution
Drug class:Miscellaneous coagulation modifiers

Medically reviewed by Drugs.com. Last updated on Oct 22, 2021.

Indications and Usage for Wilate, von Willebrand Factor/Coagulation Factor VIII Complex

WILATE is indicated in children and adults with von Willebrand disease for:

• On-demand treatment and control of bleeding episodes
• Perioperative management of bleeding

WILATE is indicated in adolescents and adults with hemophilia A for:

• Routine prophylaxis to reduce the frequency of bleeding episodes
• On-demand treatment and control of bleeding episodes

Wilate, von Willebrand Factor/Coagulation Factor VIII Complex Dosage and Administration

For Intravenous Use after Reconstitution

Dose

• Initiate treatment under the supervision of a physician experienced in the treatment of coagulation disorders.
• Each vial of WILATE contains the labeled amount in International Units (IU) of von Willebrand factor (VWF) activity as measured with the Ristocetin cofactor assay (VWF:RCo), and coagulation factor VIII (FVIII) activity measured with the chromogenic substrate assay.
• The number of units of VWF:RCo and FVIII activities administered is expressed in IU, which is related to the current WHO standards for VWF and FVIII products. VWF:RCo and FVIII activities in plasma are expressed either as a percentage (relative to normal human plasma) or in IU (relative to the International Standards for VWF:RCo and FVIII activities in plasma). One IU of VWF:RCo activity is equivalent to the quantity of VWF:RCo in one mL of normal human plasma. One IU of FVIII activity is defined by the quantity of Factor VIII in one mL of normal human pooled plasma. The ratio between VWF:RCo and FVIII activities in WILATE is approximately 1:1.

VWD

• Calculate the required dosage of VWF:RCo, based on the empirical finding that 1 IU VW...